出血高危风险非ST段抬高型急性心肌梗死患者应用磺达肝癸钠的临床研究(4)
[8]杨雪松，曹红涛，杜云蕙，等.磺达肝癸酸钠对急性冠脉综合征介入治疗术后的临床分析[J].昆明医学院学报，2011，32(6)：98-100.
[9] Reith S，Marx N，Kersten A.Acute coronary syndrome[J].Deutsche Medizinische Wochenschrift，2015，140(2)：97-103.
[10] Szummer K，Oldgren J，Lindhagen L，et al.Association between the use of fondaparinux vs low-molecular-weight heparin and clinical outcomes in patients with non-ST-segment elevation myocardial infarction[J].JAMA，2015，313(7)：707-716.
[11] Hackett C T，Ramanathan R S，Malhotra K，et al.Safety of venous thromboembolism prophylaxis with fondaparinux in ischemic stroke[J].Thromb Res，2015，135(2)：249-254.
[12] Laurent M，Joimel U，Varin R，et al.Comparative study of the effect of rivaroxaban and fondaparinux on monocyte’s coagulant activity and cytokine release[J].Exp Hematol Oncol，2014，3(1)：30.
[13] Puymirat E，Schiele F，Steg P G，et al.Determinants of improved one-year survival in non-ST- segment elevation myocardial infarction patients：insights from the French FAST-ME program over 15 years[J].Int J Cardiol，2014，177(1)：281-286.
[14] Bueno H， Sinnaeve P， Annemans L， et al.Opportunities for improvement in anti-thrombotic therapy and other strategies for the management of acute coronary syndromes：insights from EPIOR，an international study of current practice patterns[J].Eur Hart J Acute Cardiovasc Care，2015，pii：2048872614565912.
[15] Tvito A，Bakchoul T，Rowe J M，et al.Severe and persistent heparin-induced thrombocytopenia despite fondaparinux treatment[J].Am J Hematol，2015，90(7)：675-678.
(收稿日期：2015-02-02) (本文编辑：欧丽), http://www.100md.com(刘宇 李艳 李贵才 孙桂锋 汪鲁华)
[9] Reith S，Marx N，Kersten A.Acute coronary syndrome[J].Deutsche Medizinische Wochenschrift，2015，140(2)：97-103.
[10] Szummer K，Oldgren J，Lindhagen L，et al.Association between the use of fondaparinux vs low-molecular-weight heparin and clinical outcomes in patients with non-ST-segment elevation myocardial infarction[J].JAMA，2015，313(7)：707-716.
[11] Hackett C T，Ramanathan R S，Malhotra K，et al.Safety of venous thromboembolism prophylaxis with fondaparinux in ischemic stroke[J].Thromb Res，2015，135(2)：249-254.
[12] Laurent M，Joimel U，Varin R，et al.Comparative study of the effect of rivaroxaban and fondaparinux on monocyte’s coagulant activity and cytokine release[J].Exp Hematol Oncol，2014，3(1)：30.
[13] Puymirat E，Schiele F，Steg P G，et al.Determinants of improved one-year survival in non-ST- segment elevation myocardial infarction patients：insights from the French FAST-ME program over 15 years[J].Int J Cardiol，2014，177(1)：281-286.
[14] Bueno H， Sinnaeve P， Annemans L， et al.Opportunities for improvement in anti-thrombotic therapy and other strategies for the management of acute coronary syndromes：insights from EPIOR，an international study of current practice patterns[J].Eur Hart J Acute Cardiovasc Care，2015，pii：2048872614565912.
[15] Tvito A，Bakchoul T，Rowe J M，et al.Severe and persistent heparin-induced thrombocytopenia despite fondaparinux treatment[J].Am J Hematol，2015，90(7)：675-678.
(收稿日期：2015-02-02) (本文编辑：欧丽), http://www.100md.com(刘宇 李艳 李贵才 孙桂锋 汪鲁华)